Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(36 sites)
United States
The Angeles Clinic and Research Institute, Los Angeles, California Valkyrie Clinical Trials, Los Angeles, California Dana Farber Cancer Institute, Boston, Massachusetts Cancer and Hematology Centers of Western Michigan-Start Midwest, Grand Rapids, Michigan Hackensack University Medical Center, Hackensack, New Jersey Nyu Langone Health - Long Island Hospital, Mineola, New York Laura and Isaac Perlmutter Cancer Center, New York, New York University of Pennsylvania, Philadelphia, Pennsylvania Lifespan Cancer Research Institute, Providence, Rhode Island University of Texas Md Anderson Cancer Center, Houston, Texas South Texas Accelerated Research Therapeutics, San Antonio, Texas Denmark
Rigshospitalet Uni of Hospital of Copenhagen, Copenhagen Herlev Og Gentofte Hospital, Herlev Odense University Hospital, Odense C France
Institut Gustave Roussy, Villejuif Italy
Fondazione Irccs Istituto Nazionale Dei Tumori, Milan Irccs Istituto Clinico Humanitas, Rozzano Centro Ricerche Cliniche Di Verona, Verona Japan
Kansai Medical University Hospital, Hirakata National Cancer Center Hospital, Tokyo The Cancer Institute Hospital of Jfcr, Tokyo Spain
Start Barcelona, Barcelona Hospital General Universitario Vall D Hebron, Barcelona Fundacion Jimenez Diaz University Hospital, Madrid Hospital Universitario 12 de Octubre, Madrid Centro Integral Oncologico Clara Campal, Madrid Switzerland
Istituto Oncologico Della Svizzera Italiana, Bellinzona Centre Hospitalier Universitaire Vaudois (Chuv), Lausanne Kantonsspital St. Gallen, Sankt Gallen United Kingdom
Cambridge University Hospitals Nhs Foundation Trust, Cambridge Guys and St Thomas Nhs Foundation Trust, London Imperial College Healthcare Nhs Trust - Hammersmith Hospital, London The Christie Nhs Foundation Trust Uk, Manchester Freeman Hospital Newcastle Upon Tyne Foundation Nhs Trust, Newcastle upon Tyne